Global Respiratory Syncytial Virus Vaccines Market Growth (Status and Outlook) 2023-2029

Global Respiratory Syncytial Virus Vaccines Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Respiratory Syncytial Virus Vaccines Industry Forecast” looks at past sales and reviews total world Respiratory Syncytial Virus Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Respiratory Syncytial Virus Vaccines sales for 2023 through 2029. With Respiratory Syncytial Virus Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Respiratory Syncytial Virus Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Respiratory Syncytial Virus Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Respiratory Syncytial Virus Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Respiratory Syncytial Virus Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Respiratory Syncytial Virus Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Respiratory Syncytial Virus Vaccines.
The global Respiratory Syncytial Virus Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Respiratory Syncytial Virus Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Respiratory Syncytial Virus Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Respiratory Syncytial Virus Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Respiratory Syncytial Virus Vaccines players cover Pfizer Inc.Pfizer Inc., Sanofi, Merck Sharp & Dohme, GlaxoSmithKline, SOBI, Johnson & Johnson, Bavarian Nordic, Novavax and AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Syncytial Virus Vaccines market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Palivizumab
RSVpreF PF06928316
RSVPreF3 OA (GSK3844766A)
mRNA-1345
Janssen RSV Vaccine
ResVax
Nirsevimab (MEDI8897)
MVA-BN RSV
Segmentation by application
Hospital
Clinic
Research Institute
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.Pfizer Inc.
Sanofi
Merck Sharp & Dohme
GlaxoSmithKline
SOBI
Johnson & Johnson
Bavarian Nordic
Novavax
AstraZeneca
Moderna
Codagenix
Intravacc
Alphavax

Please note: The report will take approximately 2 business days to prepare and deliver.